Researchers at Radboud University Medical Center have developed a long-read genome sequencing test capable of replacing 15 standard genetic diagnostics with a single analysis. According to a study published in the New England Journal of Medicine, this technology identifies complex mutations and epigenetic modifications that conventional short-read sequencing often misses, potentially accelerating diagnosis for the estimated 400 million people living with rare diseases worldwide.
How does long-read sequencing improve rare disease diagnosis?
Long-read sequencing provides a more complete genetic map by analyzing DNA strands up to 20,000 nucleotides long, compared to the 300-nucleotide limit of traditional methods. By reading longer segments, laboratories can assemble a more accurate genome and identify structural variants that previously remained hidden. Professor Alexander Hoischen of Radboudumc notes that this capacity allows clinicians to link complex, hard-to-find abnormalities directly to specific patient conditions, thereby increasing the overall diagnostic yield.
Approximately 80% of the more than 7,000 known rare diseases are caused by genetic mutations. Many patients currently endure years of diagnostic uncertainty and multiple rounds of testing before receiving a definitive answer.
Can one test replace multiple diagnostic procedures?
The new approach acts as a “two-in-one” solution by detecting both genetic mutations and epigenetic modifications simultaneously. Professor Christian Gilissen, a genome bioinformatics expert at Radboudumc, states that while conventional diagnostics require separate, specialized tests to identify gene function alterations, long-read sequencing captures these modifications as a byproduct of the primary analysis. This consolidation significantly reduces the time and resources required to reach a diagnosis.
What were the results of the National Undiagnosed Hackathon?
In a real-world application earlier this year, experts used long-read sequencing to evaluate 33 families during the National Undiagnosed Hackathon in the Netherlands. Within two days, the technology produced five confirmed diagnoses and identified strong leads for an additional eight families. This event demonstrated the potential for the technology to serve as a high-throughput tool in clinical settings where rapid results are necessary for patient care.
If you are currently navigating the diagnostic process for a suspected rare disease, consult with your genetic counselor about whether your clinical center offers long-read sequencing options, as availability is expanding globally.
What is the future of genetic diagnostic standards?
Dr. Lisenka Vissers, a professor of translational genomics at Radboudumc, advocates for adopting long-read sequencing as the first-choice diagnostic approach for patients suspected of having rare genetic disorders. As the technology becomes more accessible, it may shift the standard of care away from iterative, fragmented testing. This transition could help researchers better understand the genetic drivers of understudied conditions that remain difficult to characterize using current industry standards.
Frequently Asked Questions
What is the main difference between short-read and long-read sequencing?
Short-read sequencing reads DNA in small fragments of roughly 300 nucleotides, while long-read sequencing analyzes segments up to 20,000 nucleotides, allowing for a more accurate assembly of the genome.
Does this test require multiple samples?
No. The primary advantage of this new approach is that it combines multiple genetic tests into a single analysis, capturing both standard mutations and epigenetic modifications in one go.
Is this technology widely available?
While currently being used in research and specialized settings like the Radboudumc, experts are pushing for its adoption as a primary diagnostic tool in clinical environments worldwide.
Have you or a loved one been impacted by the challenges of receiving a rare disease diagnosis? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on genomic medicine.
